Latest News about NVS
Recent news which mentions NVS
   UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System
   
  
  
  August 22, 2025
  From Benzinga
 
   Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
   
  
  
  August 17, 2025
  From Motley Fool
 
   2 Dividend Stocks to Buy and Hold
   
  
  
  August 15, 2025
  From Motley Fool
 
   Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
   
  
  
  August 13, 2025
  From Benzinga
 
   P/E Ratio Insights for Novartis
   
  
  
  August 12, 2025
  From Benzinga
 
   Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder
   
  
  
  August 12, 2025
  From Benzinga
 
   Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva
   
  
  
  August 11, 2025
  From Benzinga
 
   Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
   
  
  
  August 08, 2025
  From Benzinga
 From Motley Fool
 
   3 International Dividend Stocks With High Yields
   
  
  
  July 29, 2025
  From TalkMarkets
 From Benzinga
 From Benzinga
 From Benzinga
 From Motley Fool
 
   Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
   
  
  
  July 20, 2025
  From Motley Fool
 
   Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback
   
  
  
  July 17, 2025
  From Benzinga
 
   Earnings Scheduled For July 17, 2025
   
  
  
  July 17, 2025
  From Benzinga
 From Benzinga
 From TalkMarkets
 From Benzinga
 From Benzinga
 From Benzinga
 From Motley Fool
 From Benzinga
 
   Is Pfizer Stock a Yield Trap?
   
  
  
  July 03, 2025
  From Motley Fool
 From Benzinga
 From Motley Fool
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
